Direct sequencing of SARS-coronavirus S and N genes from clinical specimens shows limited variation

J Infect Dis. 2004 Sep 15;190(6):1127-31. doi: 10.1086/422849. Epub 2004 Aug 17.

Abstract

Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) emerged, in November 2002, as a novel agent causing severe respiratory illness. To study sequence variation in the SARS-CoV genome, we determined the nucleic acid sequence of the S and N genes directly from clinical specimens from 10 patients--1 specimen with no matched SARS-CoV isolate, from 2 patients; multiple specimens from 3 patients; and matched clinical-specimen/cell-culture-isolate pairs from 6 patients. We identified 3 nucleotide substitutions that were most likely due to natural variation and 2 substitutions that arose after cell-culture passage of the virus. These data demonstrate the overall stability of the S and N genes of SARS-CoV over 3 months during which a minimum of 4 generations for transmission events occurred. These findings are a part of the expanding investigation of the evolution of how this virus adapts to a new host.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Amino Acid Substitution / genetics
  • Coronavirus Nucleocapsid Proteins
  • Genome, Viral
  • Humans
  • Membrane Glycoproteins / genetics*
  • Mutation, Missense
  • Nucleocapsid Proteins / genetics*
  • Point Mutation
  • Polymorphism, Genetic
  • RNA, Viral / genetics*
  • RNA, Viral / isolation & purification
  • Severe Acute Respiratory Syndrome / virology*
  • Severe acute respiratory syndrome-related coronavirus / genetics*
  • Severe acute respiratory syndrome-related coronavirus / isolation & purification
  • Spike Glycoprotein, Coronavirus
  • Viral Envelope Proteins / genetics*

Substances

  • Coronavirus Nucleocapsid Proteins
  • Membrane Glycoproteins
  • Nucleocapsid Proteins
  • RNA, Viral
  • Spike Glycoprotein, Coronavirus
  • Viral Envelope Proteins
  • spike glycoprotein, SARS-CoV